Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers

KRAS G12D-mutant/p53-deficient non-small-cell lung cancer (NSCLC) models are dependent on the NF-κB pathway that can be down-regulated by the proteasome inhibitor bortezomib. Two exceptional responders were observed on prior clinical trials of bortezomib, both of whom had KRAS G12D-mutant NSCLC, pro...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Cold Spring Harb Mol Case Stud
Main Authors: Drilon, Alexander, Schoenfeld, Adam J., Arbour, Kathryn C., Litvak, Anna, Ni, Ai, Montecalvo, Joseph, Yu, Helena A., Panora, Elizabeth, Ahn, Linda, Kennedy, Maureen, Haughney-Siller, Anne, Miller, Vincent, Ginsberg, Michelle, Ladanyi, Marc, Arcila, Maria, Rekhtman, Natasha, Kris, Mark G., Riely, Gregory J.
פורמט: Artigo
שפה:Inglês
יצא לאור: Cold Spring Harbor Laboratory Press 2019
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549573/
https://ncbi.nlm.nih.gov/pubmed/30936194
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/mcs.a003665
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים